Biotech

Try Jim Cramer's Action Alerts PLUS
CLICK HERE NOW

What Now, Genentech Investors?

07/23/08 - 06:59 AM EDT

Adam Feuerstein

(Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco. Adam will be speaking to attendees on Friday, Aug. 8, at 2:15 p.m. ("Biotech Investing for Individuals: How to Turn Geeky Science Into Fat Profits"); on a lunch panel on Saturday, Aug. 9, at 12:35 p.m. ("Tech and Biotech: Picks and Pans for 2008 and Beyond"); and on Sunday, Aug. 10, at 8 a.m. ("Biotech Investing for Individuals: How to Turn Geeky Science Into Fat Profits").


When Roche eventually completes the job of gobbling up Genentech (DNA - Cramer's Take - Stockpickr), minority investors in the biotech sector's No. 1 company will have roughly $44 billion to re-invest somewhere else.

Where will all that money go?

The most obvious answer is right back into the other large-cap biotech firms like Celgene (CELG - Cramer's Take - Stockpickr), Gilead Sciences (GILD - Cramer's Take - Stockpickr) and Biogen Idec (BIIB - Cramer's Take - Stockpickr), which, in turn, bodes well for the sector as a whole. More on that in a second, but first, here's an intriguing, if not a fantastical, proposal: How about into a new, mini-Genentech?

A Mini-Genentech Spinoff?

Yes, it's probably too early to think about Roche spinning off a piece of the "old" Genentech into a new, publicly traded company, but the idea isn't totally far fetched. Moreover, it might solve the thorniest issue facing the Swiss drug giant outside of defending its $89-a-share takeover price: How to retain Genentech's best and brightest scientists so that they keep on discovering new blockbuster drugs for Roche and not for someone else.

Think about it, Roche is making its move now because it wants to control 100% of Genentech's commercial operations, namely the blockbuster products Avastin, Rituxan and Herceptin, before it has to renegotiate a new marketing agreement in 2015. The weakness in the U.S. dollar works to Roche's advantage today, and the company acknowledges that the environment for Big Pharma is changing, growing more competitive.

Genentech also has one of the deepest R&D pipelines in the industry, which should help Roche grow into the future, but if the company were interested in unlocking more of the value from that pipeline -- and could get investors to share the risk and reward of early-stage drug development -- a mini-Genentech spinoff (with Roche still controlling a majority stake, of course) makes a lot of sense.

Previous «
1 2 3 4
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Headlines & Perspectives

Biotech

Go To Section Home


07/21/08
Roche Bid Could Alter Pharma's DNA

Analysts on Wall Street consider the $89-a-share offer a low-ball bid; it could spur further M&A activity in the sector, however.


07/21/08
Cramer: Drug Stocks Potent Now

Jim Cramer discusses bear market cycles and drug stocks - it's not too late to get in.


07/21/08
Roche Bids for Rest of Genentech (Update)

The offer is worth nearly $44 billion and is valued at $89 a share.


07/21/08
Genentech Bid Confirms the Trend

The biotechs look sweet in a bank-led slowdown.


07/07/08
Biotech Stocks: Second-Half '08 Preview

Here are the data and regulatory decisions that are likely to be the biggest catalysts from July to December.


08/05/08
Three Internet Stocks That Could Double

These forgotten Internet stocks are being accumulated by hedge funds.


08/15/08
The Five Dumbest Things on Wall Street

Raspberries for Apple; You'll be sorry, UBS; Fortress or Fort Knox? Wholly unappetizing Foods; give Liberty AOL or give them...


08/15/08
McCain Fund-Raising Picks Up

The GOP presidential candidate raised $27 million in July.


08/15/08
Cash-Back Cards Aren't Money in the Bank

Some credit and debit cards give you some cash back on purchases. But you need to manage it well to benefit from it.


Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now. See All

  • Cramer's Daily Booyah!
  • Before the Bell

Premium Stock Ideas